Pharmaceutical Cannabis Market
A market study ”Global Pharmaceutical Cannabis Market” examines the performance of the Global Pharmaceutical Cannabis Market 2021. It encloses an in-depth Research of the Pharmaceutical Cannabis Market state and the competitive landscape globally. This report analyzes the potential of Pharmaceutical Cannabis Market in the present and the future prospects from various angles in detail.
Global Pharmaceutical Cannabis Market Overview:
The Global Pharmaceutical Cannabis Market research report is the investigation arranged by investigators, which contain a point by point examination of drivers, limitations, and openings alongside their effect on the Pharmaceutical Cannabis Market development (2020 – 2025).
The significant key factors driving the growth of the Global Pharmaceutical Cannabis Market are rapidly progressing transformation of cannabis from herbal preparations to prescription drugs, and growing use of cannabis-based pharmaceuticals for multiple indications including inflammation, chronic pain, epilepsy, sleep disorders, anorexia, schizophrenia, and symptoms of multiple sclerosis.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/284086 .
The Global Pharmaceutical Cannabis Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global Pharmaceutical Cannabis Market is sub-segmented into THC-dominant, CBD-dominant, Balanced THC & CBD and others. On the basis of Application, the Global Pharmaceutical Cannabis Market is classified into Cancer, Arthritis, Migraine, Epilepsy and others.
In terms of the geographic analysis, The Pharmaceutical Cannabis Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Pharmaceutical Cannabis Market ecosystem results in the increasing adoption of these systems in North America.
Top Medical Industry News:
GW Pharmaceuticals (February 23, 2021) – GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex – GW Pharmaceuticals plc, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older.
TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.
“Epilepsy is reported in more than 90% of individuals with Tuberous Sclerosis Complex (TSC), and over 60% of those with seizures associated with TSC do not respond to standard anti-epileptic medicines. Today’s positive CHMP opinion brings us one step closer to a potentially life-improving new treatment option for these patients for whom EPIDYOLEX may be appropriate,” said Justin Gover, GW’s Chief Executive Officer. “This decision represents another important step for GW as we look to expand the medicine’s label in Europe. If approved, this represents the third licensed indication for GW’s medicine, broadening patient access to this rigorously tested cannabis-based medicine.”
Professor Helen Cross, Honorary Consultant in Paediatric Neurology at Great Ormond Street Hospital for Children NHS Foundation Trust, said, “This debilitating disease affects tens of thousands of patients in Europe, many of whom may benefit from alternative treatment options to achieve adequate seizure control. This decision, and the clinical data supporting the use of EPIDYOLEX in this challenging condition, offers real hope to the patients, their parents and physicians that battle this condition and the seizures it brings every day.”
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Pharmaceutical Cannabis Market Report 2021” @ https://www.businessindustryreports.com/buy-now/284086/single .
Top Leading Key in Players Global Pharmaceutical Cannabis Market: Canopy Growth, GW Pharmaceuticals, Aurora Cannabis, Aphria, MedReleaf, Insys Therapeutics, CanniMed Therapeutics, Cara Therapeutics, United Cannabis Corporation and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.
With the presence of a large pool of participants, the Global Pharmaceutical Cannabis Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). Canopy Growth, GW Pharmaceuticals, Aurora Cannabis, Aphria, MedReleaf, Insys Therapeutics, CanniMed Therapeutics, Cara Therapeutics, United Cannabis Corporation are some of the key vendors of Pharmaceutical Cannabis across the world. These players across Pharmaceutical Cannabis Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.
Region segment: Pharmaceutical Cannabis Market report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Pharmaceutical Cannabis in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/284086 .
Major Points in Table of Contents:
Global Pharmaceutical Cannabis Market Report 2021
1 Pharmaceutical Cannabis Product Definition
2 Global Pharmaceutical Cannabis Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Pharmaceutical Cannabis Shipments
2.2 Global Manufacturer Pharmaceutical Cannabis Business Revenue
2.3 Global Pharmaceutical Cannabis Market Overview
2.4 COVID-19 Impact on Pharmaceutical Cannabis Industry
3 Manufacturer Pharmaceutical Cannabis Business Introduction
3.1 Canopy Growth Corporation Pharmaceutical Cannabis Business Introduction
3.2 GW Pharmaceuticals, plc Pharmaceutical Cannabis Business Introduction
3.3 Aurora Cannabis, Inc. Pharmaceutical Cannabis Business Introduction
3.4 Aphria, Inc. Pharmaceutical Cannabis Business Introduction
3.5 MedReleaf Corporation Pharmaceutical Cannabis Business Introduction
3.6 Insys Therapeutics, Inc. Pharmaceutical Cannabis Business Introduction
………………. Request free sample to get a complete Table of Content
BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.
Business Industry Reports
Pune – India
This release was published on openPR.